GlobeNewswire by notified

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Share

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Obexelimab is a novel bifunctional antibody with first-in-class potential to treat autoimmune diseases

MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab.

Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain and uses Xencor's XmAb® Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which are important components in the immune system. Xencor demonstrated through early-stage clinical studies that obexelimab effectively inhibits B-cell function without depleting the cells and generates an encouraging treatment effect in patients with multiple autoimmune diseases.

“Zenas is advancing a broad pipeline of differentiated drug candidates that are intended to bring best-in-class innovation to patients with underserved medical needs,” said Hua Mu, Ph.D., MD, president and chief executive officer at Zenas. “Today, we are pleased to add obexelimab to our portfolio, and based on its clinical profile, we believe it is positioned as a first-in-class candidate with the potential to treat numerous autoimmune diseases.”

“Obexelimab’s highly potent and broad blockade of B-cell activation—without depleting B cells—differentiates it from other B-cell targeting therapies, and it has demonstrated disease-modifying activity in settings where B-cell inhibition is a proven strategy,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “In Zenas BioPharma, we have found a partner committed to broadly and aggressively developing therapeutics like obexelimab for patients with autoimmune diseases, enabling Xencor’s continued focus on the growing opportunities provided by our XmAb bispecific antibody and cytokine pipeline.”

Under the terms of the new agreement, Zenas will issue to Xencor a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor’s total equity in Zenas would be 15% of its fully diluted capitalization following the closing of Zenas’ next round of equity financing, subject to certain requirements. Xencor previously received equity in Zenas under a separate license agreement. Xencor is also eligible to receive up to $480 million based on the achievement of certain clinical development, regulatory and commercialization milestones and is eligible to receive tiered, mid-single digit to mid-teen percent royalties upon commercialization of obexelimab, dependent on geography. Zenas will have sole responsibility for advancing the research, development, regulatory and commercial activities of obexelimab worldwide.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Xencor Forward-Looking Statements

Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by our use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” and similar terms, or by express or implied discussions relating to the development of obexelimab as a potential treatment for patients with autoimmune diseases; the commercial potential of obexelimab; the safety, tolerability, efficacy and pharmacokinetics of obexelimab; the quotations from Xencor’s president and chief executive officer; and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2020 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Contacts

Xencor Investor Contact:
Charles Liles
cliles@xencor.com

Xencor Media Contact:
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Zenas Investor Contact:
IR@zenasbio.com

Zenas Media Contact:
Lauren Bartlett
lauren.bartlett@zenasbio.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AMG Advanced Metallurgical Group N.V. Announces AMG Brazil Mine Site has Reached Over 1,000 Days Without a Lost Time Incident1.12.2021 22:00:00 CET | Press release

Amsterdam, 1December 2021--- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce that the AMG Brazil Mine Site has reached over 1,000 days without a Lost Time Incident. Dr. Heinz Schimmelbusch, Chairman of the Management Board and CEO, said, “At AMG, the health and safety of our employees is the number one value. “Zero incidents” for an extended period of time is an extraordinary achievement. This incredible milestone was only possible because of each employee’s discipled attitude and proactive responsibility for creating a safe working environment.” “AMG Brazil has a certified HSE management system that is mature, robust, well developed, and efficient at preventing incidents by fostering identification and mitigation of risks and hazards as we constantly train our workforce to perform its duties safely. The system alone would never achieve such a result without our workers’ preemptive behavior and commitment to care for themselves and their

Sophi.io Wins at WAN-IFRA Digital Media Awards Worldwide 20211.12.2021 17:51:16 CET | Press release

Sophi Dynamic Paywall wins global award for Best Paid Media Strategy TORONTO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Sophi.io, The Globe and Mail’s artificial intelligence-based automation, optimization and prediction engine, won WAN-IFRA’s 2021 Digital Media Awards Worldwide award in the Best Paid Media Strategy category for Sophi Dynamic Paywall, its real-time, personalized paywall engine that analyses both content characteristics and user behaviour to determine when to ask a reader for money or an email address, and when to leave them alone. The judges unanimously selected Sophi Dynamic Paywall as the winner, with one judge commenting: “What Globe and Mail did is state of the art and what I appreciate most is that they permanently tested against the old paywall so those results are really, really sustainable.” The World Association of News Publishers (WAN-IFRA)’s Digital Media Awards Worldwide is the news media industry’s global digital media competition. The worldwide winners are select

Wolters Kluwer completes divestment U.S. legal education business1.12.2021 17:35:00 CET | Press release

Wolters Kluwer completes divestment U.S. legal education business December 1, 2021 — Wolters Kluwer today announces that it has completed the divestment of its U.S. legal education business to Transom Capital Group. As previously announced on September 27, Wolters Kluwer intends to deploy the post-tax proceeds towards additional share repurchases in order to mitigate the expected dilution to adjusted earnings per share from the sale. To this end, Wolters Kluwer has now granted a mandate to a third-party to execute up to €60 million in share buybacks on our behalf in the remainder of this year (the period starting December 2, 2021, up to and including December 29, 2021). Including this mandate, when completed, total share repurchases will reach €410 million in 2021. This mandate is governed by the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and Wolters Kluwer’s Articles of Association. Repurchased shares are added to and held as treasury shares and a

HMNC Brain Health to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference1.12.2021 16:37:31 CET | Press release

MUNICH, Germany, Dec. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at H.C. Wainwright’s 2nd Annual Psychedelics Conference on Monday, December 6th, 2021. In addition, Dr. Eriksson will participate in the ‘Future of Mental Healthcare’ panel at 2:30 p.m. Eastern Time. To attend, please register here. HMNC Brain Health’s virtual presentation will be available beginning Monday, December 6th at 7:00 a.m. Eastern Time and is accessible through the following webcast link: https://journey.ct.events/view/d77f2d7d-bff2-4d9a-8e89-620a24d1f35a. A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webca

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab1.12.2021 15:03:00 CET | Press release

AGC Biologics to produce Procizumab for early and late clinical phases at company’s Chiba and Copenhagen facilities Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure. Under the terms of the agreement, the companies will collaborate to transfer and optimize the manufacturing process for Procizumab. AGC Biologics will manufacture the clinical trial materials at its site in Chiba and transfer to its Copenhagen facility for all late phase activities including commercialization, to support early and late clinical phases and launch readiness of 4TEEN4’s monoclonal antibody. “We look forward to partnering with 4TEEN4

Kalmar’s proven straddle carrier technology to enhance operational capabilities at Kingston Freeport Terminal, Jamaica1.12.2021 15:00:00 CET | Press release

CARGOTEC CORPORATION, PRESS RELEASE, 1 DECEMBER 2021 AT 4 PM (EET) Kalmar, part of Cargotec, has signed a contract to supply the Kingston Freeport Terminal Limited (KFTL) with four diesel-electric straddle carriers for use at their terminal in Kingston, Jamaica. The order was booked in Cargotec's 2021 Q4 order intake with delivery scheduled to be completed during Q3 2022. KFTL is a strategic transhipment hub in the Caribbean, located at the exit of the Panama Canal and the crossroads of the North/South and East/West lines. The terminal was established in 2015, and it is part of Terminal Link, a joint venture between The CMA CGM Group, a world leader in shipping and logistics, and China Merchants Port (CMP). The four Kalmar Straddle Carriers are part of a progressive fleet renewal strategy geared to improve performance and reliability in the terminal's operation. KFTL’s equipment fleet already includes Kalmar straddle carriers, reachstackers, empty container handlers and terminal tracto

Sinch carries out second part of the directed new share issue of approximately 40 million shares announced on 30 September 20211.12.2021 14:50:00 CET | Press release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Stockholm, Sweden – December 1, 2021 - Sinch AB (publ) (“Sinch” or the “Company”) carries out a directed new share issue through the issuance of 21 million new shares for a total consideration of approximately SEK 3,469 million. The new share issue constitutes the second part of the SEK 6.6 billion new share issue of in total 40,077,841 shares (the “Shares”) announced on 30 September 2021, the proceeds of which are used to partially fund the acquisition of Pathwire. The subscribers consisted of institutional investors, among others the Canada Pension Plan Investment Board (“CPP Investments”), Temasek, SeaTown Master Fund (“SeaTown”), and SB Northstar LP,